Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease
- 1 June 1992
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 339 (8806), 1375-1377
- https://doi.org/10.1016/0140-6736(92)91196-f
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- Debrisoquine oxidation in Parkinson's diseaseActa Neurologica Scandinavica, 1991
- The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspectsPharmacology & Therapeutics, 1990
- Detection of debrisoquine hydroxylation phenotypesThe Lancet, 1990
- Identification of the primary gene defect at the cytochrome P450 CYP2D locusNature, 1990
- 4′-Alkylated analogs of 1-methyl-4-phenylpyridinium ion are potent inhibitors of mitochondrial respirationBiochemical and Biophysical Research Communications, 1990
- Oxidative polymorphism of debrisoquine in Parkinson's disease.Journal of Neurology, Neurosurgery & Psychiatry, 1990
- Mitochondrial Complex I Deficiency in Parkinson's DiseaseJournal of Neurochemistry, 1990
- MPTP, the neurotoxin inducing parkinson's disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufI, P450db1) catalyzing debrisoquine 4-hydroxylationBiochemical and Biophysical Research Communications, 1987
- Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridineLife Sciences, 1985
- Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidaseBiochemical and Biophysical Research Communications, 1984